Innovent Biologics and Sanofi Announce License Deal for Drug Development in China
China-based biotech firm Innovent Biologics Inc. (HKG: 1801) and France’s Sanofi SA (NASDAQ: SNY) have...
Eli Lilly Reports First Quarterly Revenue Dip in Two Years, China Sales Plunge
US-based Eli Lilly & Co. (NYSE: LLY) released its Q2 2022 financial report, revealing a...
Novo Nordisk’s H1 2022 Results Show Strong Global Sales Growth, China Sales Dip
Denmark-based Novo Nordisk (NYSE: NVO) released its H1 2022 financial results, reporting a 14% year-on-year...
Shanghai Pharmaceuticals Partners with HKSTP and Shanghai Biomedicine Fund on R&D Collaboration
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), a leading Chinese pharmaceutical company, has entered into a...
Zhongsheng Pharmaceutical Completes Phase I Study of RAY1216 for COVID-19 Treatment
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the completion of subject enrollment and...
CSPC Pharmaceutical’s rhTNK-tPA Meets Primary Endpoint in Stroke Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the Phase III clinical study for...
HeNan Genuine Biotech Files for IPO to Fund Azvudine Commercialization
China-based HeNan Genuine Biotech Co., Ltd has filed for an initial public offering (IPO) with...
Innovent Biologics’ Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved
Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding...
Hybio Pharmaceutical’s HY3000 Nasal Spray for COVID-19 Enters NMPA Review
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its clinical trial filing for HY3000...
GenScript’s Legend Biotech Appoints Three New Directors to Board
Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary...
Boehringer Ingelheim Wins Patent Infringement Ruling Against HEC Over Trajenta
The China National Intellectual Property Administration (CNIPA) has ruled in favor of German pharmaceutical giant...
Zelgen’s Jacktinib Hits Phase IIb Endpoint in Myelofibrosis Study
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a pivotal Phase...
Wision A.I.’s Polyp Detection Software Secures NMPA Approval for Colonoscopy Use
The National Medical Products Administration (NMPA) has approved China-based Wision A.I.’s intestinal polyp electronic colonoscopy...
Ethicon’s Hemostatic Granules Win NMPA Approval for Endoscopic Surgery Use
The National Medical Products Administration (NMPA) has granted marketing approval to U.S. medical device firm...
Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues
China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued...
WuXi Biologics Partners with AstraZeneca for Local Production of Evusheld
China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...
Structure Therapeutics Oversubscribes USD33m on Top of USD100m Series B Round
Structure Therapeutics, a Sino-US firm formerly known as ShouTi Inc., announced the oversubscription of USD33...
Ascletis Pharma’s ASC10 Receives IND Approval for COVID-19 Treatment in US and China
China-based Ascletis Pharma Inc. (HKG: 1672) has provided updates on the clinical progress of ASC10,...
ProfoundBio Receives FDA Approval for PRO1184, Appoints New CMO
China-based macromolecular targeted therapy developer ProfoundBio (Suzhou) Co., Ltd announced that it has received clinical...
AstraZeneca’s H1 2022 Revenues Surge 48%, Led by Oncology and Vaccines
UK-based AstraZeneca (AZ, NASDAQ: AZN) released its financial report for H1 2022, showing a 48%...